Week of March 15th, 2021 | Vol. 10, Issue 11 |
|
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events
Quick Links
Contact Information
Managing Director
Business Development
Managing Director
Head of M&A and Capital Advisory
|
|
Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.
|
|
For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
|
|
MARKET REPORTS
Recent Materials Providing Insight Into Healthcare Related Industries
|
|
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
|
|
Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics
Project Aspen
Sell-side | CDMO | Multinational CDMO headquartered in US
Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse
Project Bulldog
Sell-side | Pharma Services| Life sciences consulting firm
|
|
ANI Pharmaceuticals, Inc. today announced that it has signed a definitive agreement to acquire Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities for $163.5 million, including $89.5 million in cash and $74 million in equity plus two potential future cash earn-outs of up to $46.5 million. The transaction has been approved by the ANI Board of Directors and is expected to close in the second half of 2021, subject to regulatory approvals and approval by ANI shareholders as required by Nasdaq listing standards as described below. Equity holders of Novitium have approved the transaction.
“Strengthening our well-established Generics business with enhanced development capabilities and increased focus on niche opportunities is a key pillar of ANI’s growth strategy. The acquisition of Novitium aligns with this strategy, adding a best-in-class R&D engine that delivers sustainable growth through new product launches and offering upside through niche 505(b)(2) opportunities. The addition of a U.S. based, state-of-the-art manufacturing facility and enhanced scale to our CDMO business are other attractive advantages of this acquisition. We also look forward to welcoming Samy, Chad, Vijay and the entire Novitium team to ANI,” stated Nikhil Lalwani, President and CEO.
|
|
RECENT INDUSTRY TRANSACTIONS
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
|
|
Pharma & Biotech
10 transactions totaling $1,379 million
Supplies, Equipment & Services
25 transactions totaling $1,041 million
Healthcare IT & Managed Care
14 transactions totaling $63 million
Healthcare Facilities & Distributors
6 transactions totaling $7 million
|
|
Pharma & Biotech
31 transactions totaling $860 million
Supplies, Equipment & Services
28 transactions totaling $371 million
Healthcare IT & Managed Care
22 transactions totaling $461 million
Healthcare Facilities & Distributors
3 transactions totaling $227 million
|
|
Pharma & Biotech
27 transactions totaling $1,288 million
Supplies, Equipment & Services
9 transactions totaling $1,312 million
Healthcare IT & Managed Care
5 transactions totaling $3,689 million
Healthcare Facilities & Distributors
3 transactions totaling $93 million
|
|
INDUSTRY TRADING COMPS
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
|
|
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.
For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table.
Note: data reflects prior week close.
|
|
|
RECENT INDUSTRY TRANSACTIONS
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
|
|
March 13, 2021 - Contract Pharma
The UK study enrolled more than 15,000 participants between 18-84 years of age. Efficacy was 96.4% against the original virus strain and 86.3% against the B.1.1.7/501Y.V1 variant circulating in the U.K (post hoc). The primary efficacy endpoint demonstrated an overall vaccine efficacy of 89.7%.
March 10, 2021 - Fierce Pharma
Thermo Fisher will upgrade its bioprocessing operations with more than $600 million in capital investments, plus at least 1,500 new hires, the company said Wednesday. The expansion, which will more than double the CDMO's production capacity, will support both short-term COVID-19 demand and bolster the company's long-term efforts to develop biologics and vaccines for other diseases.
March 10, 2021 - Fierce Healthcare
Ambulnz, a company that offers medical mobility and transportation services, plans to go public through a merger with a blank check company in a deal that will value the combined entity at $1.1 billion. The company, which will be renamed DocGo, plans to merge with special purpose acquisition company (SPAC) Motion Acquisition Corp. Upon closing of the transaction, DocGo is expected to be listed on Nasdaq under the new ticker symbol "DCGO."
March 8, 2021 - Fierce Pharma
Cost watchdogs at England’s National Institute for Health and Care Excellence (NICE) have clashed repeatedly with pharma companies over the price of new medicines. But a review of Novartis’ expensive gene therapy Zolgensma shows the agency is looking at more than just cost.
|
|
Welcome to Bourne, let's talk.
Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.
|
|
|
|
|
|
|
